Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 26

1.

Slow or fast viral load decay as a predictor of residual viremia level in HIV-infected patients undergoing successful first-line cART.

Amendola A, Bibbolino G, Navarra A, Pisciotta M, Marsella P, Pinnetti C, Abbate I, Rozera G, Mondi A, Antinori A, Capobianchi MR, Girardi E, Ammassari A.

New Microbiol. 2017 Oct;40(4):234-241.

2.

Dynamics and phylogenetic relationships of HIV-1 transmitted drug resistance according to subtype in Italy over the years 2000-14.

Fabeni L, Alteri C, Di Carlo D, Orchi N, Carioti L, Bertoli A, Gori C, Forbici F, Continenza F, Maffongelli G, Pinnetti C, Vergori A, Mondi A, Ammassari A, Borghi V, Giuliani M, De Carli G, Pittalis S, Grisetti S, Pennica A, Mastroianni CM, Montella F, Cristaudo A, Mussini C, Girardi E, Andreoni M, Antinori A, Ceccherini-Silberstein F, Perno CF, Santoro MM; SENDIH Study Group; SENDIH (Studio Epidemiologico Nuove Diagnosi Infezione da HIV) Study Group.

J Antimicrob Chemother. 2017 Oct 1;72(10):2837-2845. doi: 10.1093/jac/dkx231.

PMID:
29091206
3.

Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA.

Rossetti B, Meini G, Bianco C, Lamonica S, Mondi A, Belmonti S, Fanti I, Ciccarelli N, Di Giambenedetto S, Zazzi M, De Luca A.

J Clin Virol. 2017 Jun;91:18-24. doi: 10.1016/j.jcv.2017.03.018. Epub 2017 Mar 23.

PMID:
28395180
4.

Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M).

Di Giambenedetto S, Fabbiani M, Quiros Roldan E, Latini A, D'Ettorre G, Antinori A, Castagna A, Orofino G, Francisci D, Chinello P, Madeddu G, Grima P, Rusconi S, Di Pietro M, Mondi A, Ciccarelli N, Borghetti A, Focà E, Colafigli M, De Luca A, Cauda R; Atlas-M Study Group.

J Antimicrob Chemother. 2017 Apr 1;72(4):1163-1171. doi: 10.1093/jac/dkw557.

PMID:
28093483
5.

Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients.

Gagliardini R, Fabbiani M, Colafigli M, D'Avino A, Mondi A, Borghetti A, Lamonica S, Cauda R, De Luca A, Di Giambenedetto S.

J Chemother. 2017 Oct;29(5):299-307. doi: 10.1080/1120009X.2016.1269040. Epub 2016 Dec 26.

PMID:
28019192
6.

Risk of Chronic Kidney Disease among Patients Developing Mild Renal Impairment during Tenofovir-Containing Antiretroviral Treatment.

Lapadula G, Bernasconi DP, Casari S, Maggiolo F, Cauda R, Di Pietro M, Ladisa N, Sighinolfi L, Dal Zoppo S, Sabbatini F, Soria A, Pezzoli C, Mondi A, Costarelli S, Valsecchi MG, Torti C, Gori A; Italian MASTER cohort.

PLoS One. 2016 Sep 15;11(9):e0162320. doi: 10.1371/journal.pone.0162320. eCollection 2016.

7.

Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients.

Fabbiani M, Di Giambenedetto S, Poli A, Borghetti A, Castagna A, Mondi A, Galizzi N, Maillard M, Gori A, Cauda R, De Luca A, Gianotti N.

J Infect. 2016 Dec;73(6):619-623. doi: 10.1016/j.jinf.2016.08.011. Epub 2016 Aug 26. No abstract available.

PMID:
27575581
8.

Neuropsychological screening tools in Italian HIV+ patients: a comparison of Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE).

Milanini B, Ciccarelli N, Fabbiani M, Baldonero E, Limiti S, Gagliardini R, Borghetti A, D'Avino A, Mondi A, Colafigli M, Cauda R, Di Giambenedetto S.

Clin Neuropsychol. 2016 Jan-Dec;30(sup1):1457-1468. Epub 2016 May 16.

PMID:
27180611
9.

Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy.

Borghetti A, Baldin G, Ciccullo A, Gagliardini R, D'Avino A, Mondi A, Ciccarelli N, Lamonica S, Fanti I, Trecarichi E, Fabbiani M, Cauda R, De Luca A, Di Giambenedetto S.

J Antimicrob Chemother. 2016 Aug;71(8):2359-61. doi: 10.1093/jac/dkw147. Epub 2016 May 4. No abstract available.

PMID:
27147306
10.

Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen.

Fabbiani M, Zaccarelli M, Latini A, Sterrantino G, D'Ettorre G, Grima P, Mondi A, Rossetti B, Borchi B, Giuliani M, Antinori A, De Luca A, Di Giambenedetto S.

HIV Med. 2016 May;17(5):385-9. doi: 10.1111/hiv.12313. Epub 2015 Sep 22.

PMID:
26394902
11.

Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study.

Mondi A, Fabbiani M, Ciccarelli N, Colafigli M, D'Avino A, Borghetti A, Gagliardini R, Cauda R, De Luca A, Di Giambenedetto S.

J Antimicrob Chemother. 2015;70(6):1843-9. doi: 10.1093/jac/dkv037. Epub 2015 Feb 26.

PMID:
25885326
12.

Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility.

Fabbiani M, Grima P, Milanini B, Mondi A, Baldonero E, Ciccarelli N, Cauda R, Silveri MC, De Luca A, Di Giambenedetto S.

Antivir Ther. 2015;20(4):441-7. doi: 10.3851/IMP2926. Epub 2014 Dec 17.

PMID:
25516553
13.

Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre.

Borghetti A, Mondi A, Piccoli B, Gagliardini R, Lamonica S, Ciccarelli N, D'Avino A, Pallavicini F, Cauda R, De Luca A, Fabbiani M, Di Giambenedetto S.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19817. doi: 10.7448/IAS.17.4.19817. eCollection 2014.

14.

Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial.

Fabbiani M, Di Giambenedetto S, Quiros-Roldan E, Latini A, Vullo V, Antinori A, Castagna A, Orofino G, Francisci D, Grilli E, Madeddu G, Grima P, Rusconi S, Del Pin B, Mondi A, Borghetti A, Focà E, Colafigli M, De Luca A, Cauda R.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19808. doi: 10.7448/IAS.17.4.19808. eCollection 2014.

15.

Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA.

Bianco C, Meini G, Rossetti B, Lamonica S, Mondi A, Belmonti S, Fanti L, Ciccarelli N, Di Giambenedetto S, Zazzi M, De Luca A.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19791. doi: 10.7448/IAS.17.4.19791. eCollection 2014.

16.

Liver fibrosis is associated with cognitive impairment in HIV-positive patients.

Ciccarelli N, Fabbiani M, Grima P, Limiti S, Fanti I, Mondi A, Gagliardini R, D'Avino A, Borghetti A, Cauda R, Di Giambenedetto S.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19722. doi: 10.7448/IAS.17.4.19722. eCollection 2014.

17.

Prevalence of osteoporosis and predictors of low BMD in a cohort of HIV-1-infected patients in Rome: features of a population at high risk.

D'Avino A, Lassandro A, Lamonica S, Piccoli B, Fabbiani M, Mondi A, Gagliardini R, Borghetti A, Fanti I, Pallavicini F, Cauda R, Di Giambenedetto S.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19570. doi: 10.7448/IAS.17.4.19570. eCollection 2014.

18.

Ophthalmic artery resistance index is increased in HIV-Infected patients and is influenced by protease inhibitors exposure.

Fabbiani M, Grima P, Borghetti A, Colafigli M, D'Avino A, Mondi A, Gagliardini R, De Luca A, Cauda R, Di Giambenedetto S.

J Infect. 2014 May;68(5):500-3. doi: 10.1016/j.jinf.2014.01.012. Epub 2014 Feb 6. No abstract available.

PMID:
24509141
19.

Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients.

Fabbiani M, Zaccarelli M, Grima P, Prosperi M, Fanti I, Colafigli M, D'Avino A, Mondi A, Borghetti A, Fantoni M, Cauda R, Di Giambenedetto S.

BMC Infect Dis. 2014 Jan 13;14:26. doi: 10.1186/1471-2334-14-26.

20.

Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study).

Fabbiani M, Mondi A, Colafigli M, D'Ettorre G, Paoletti F, D'Avino A, Ciccarelli N, Sidella L, Murri R, Fortuna S, Vullo V, Cauda R, De Luca A, Di Giambenedetto S.

Scand J Infect Dis. 2014 Jan;46(1):34-45. doi: 10.3109/00365548.2013.840920. Epub 2013 Oct 28.

PMID:
24161018

Supplemental Content

Support Center